Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy

American Journal of Hematology

Volumn 88, Issue 9, 2013, Pages 774-779

  Ahn, Jae Sook ^a   Yang, Deok Hwan ^a   Duk Choi, Yoo ^a   Jung, Sung Hoon ^a   Yhim, Ho Young ^b   Kwak, Jae Yong ^b   Sung Park, Ho ^b   Shin, Myung Geun ^a   Kim, Yeo Kyeoung ^a   Kim, Hyeoung Joon ^a   Lee, Je Jung ^a,c  

^a Chonnam National University Research Institute of Medical Sciences   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

^c Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; ASTHENIA; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCIDENCE; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DNA, VIRAL; DOXORUBICIN; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84882725507     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23507     Document Type: Article

References (21)

1. Shah KM, Young LS. Epstein-Barr virus and carcinogenesis: Beyond Burkitt's lymphoma. Clin Microbiol Infect 2009;15:982-988.
2. Castillo JJ, Beltran BE, Miranda RN, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: What we know so far. Oncologist 2011;16:87-96.
3. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000;18:3707-3721.
4. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases. Am J Hematol 2008;83:804-809.
5. Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008. 439 p. p.
6. Morales D, Beltran B, De Mendoza FH, et al. Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma 2010;51:66-72.
7. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007;110:972-978.
8. Yoshino T, Nakamura S, Matsuno Y, et al. Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma. Cancer Sci 2006;97:163-166.
9. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: A study of 96 patients. Clin Cancer Res 2007;13:5124-5132.
10. Beltran BE, Castillo JJ, Morales D, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: A case series from Peru. Am J Hematol 2011;86:663-667.
11. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
12. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
13. Lages CS, Suffia I, Velilla PA, et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol 2008;181:1835-1848.
14. Oyama T, Ichimura K, Suzuki R, et al. Senile EBV+ B-cell lymphoproliferative disorders: A clinicopathologic study of 22 patients. Am J Surg Pathol 2003;27:16-26.
15. Gibson SE, Hsi ED. Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: An uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 2009;40:653-661.
16. Hoeller S, Tzankov A, Pileri SA, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 2010;41:352-357.
17. Wong HH, Wang J. Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly. Leuk Lymphoma 2009;50:335-340.
18. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-123.
19. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126.
20. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
21. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012;13:196-206.